These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 3677300)

  • 1. Occurrence of circulating 7-deoxyaglycone metabolites of 4'-deoxydoxorubicin in man.
    Cummings J; Kerr DJ; Kaye SB
    Cancer Chemother Pharmacol; 1987; 20(3):263-4. PubMed ID: 3677300
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Method for the determination of 4'-deoxydoxorubicin, 4'-deoxydoxorubicinol and their 7-deoxyaglycones in human serum by high-performance liquid chromatography.
    Cummings J
    J Chromatogr; 1985 Jun; 341(2):401-9. PubMed ID: 4030989
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Marked inter-patient variation in adriamycin biotransformation to 7-deoxyaglycones: evidence from metabolites identified in serum.
    Cummings J; Milstead R; Cunningham D; Kaye S
    Eur J Cancer Clin Oncol; 1986 Aug; 22(8):991-1001. PubMed ID: 3770056
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Determination of adriamycin, adriamycinol and their 7-deoxyaglycones in human serum by high-performance liquid chromatography.
    Cummings J; Stuart JF; Calman KC
    J Chromatogr; 1984 Nov; 311(1):125-33. PubMed ID: 6520153
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative cardiotoxicity and antitumour activity of doxorubicin (adriamycin) and 4'-deoxydoxorubicin and the relationship to in vivo disposition and metabolism in the target tissues.
    Cummings J; Willmott N; More I; Kerr DJ; Morrison JG; Kaye SB
    Biochem Pharmacol; 1987 May; 36(9):1521-6. PubMed ID: 3579988
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Improved high-performance liquid chromatography assay of doxorubicin: detection of circulating aglycones in human plasma and comparison with thin-layer chromatography.
    Brenner DE; Galloway S; Cooper J; Noone R; Hande KR
    Cancer Chemother Pharmacol; 1985; 14(2):139-45. PubMed ID: 3971478
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics and metabolism of doxorubicin after short-term infusions in lymphoma patients.
    Andersen A; Holte H; Slørdal L
    Cancer Chemother Pharmacol; 1999; 44(5):422-6. PubMed ID: 10501917
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rapid quantitative determination of doxorubicin and its metabolites in biological samples.
    Sqalli A; Labat C; Oustrin J; Houin G; Coulais Y; Bugat R; Carton P
    Ann Biol Clin (Paris); 1989; 47(2):63-6. PubMed ID: 2735565
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics and metabolism of iodo-doxorubicin and doxorubicin in humans.
    Mross K; Mayer U; Hamm K; Burk K; Hossfeld DK
    Eur J Clin Pharmacol; 1990; 39(5):507-13. PubMed ID: 2076745
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Plasma pharmacokinetics of adriamycin and its metabolites in humans with normal hepatic and renal function.
    Benjamin RS; Riggs CE; Bachur NR
    Cancer Res; 1977 May; 37(5):1416-20. PubMed ID: 856462
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacology of N,N-di(n-butyl)adriamycin-14-valerate in the rat.
    Han G; Israel M; Seshadri R; Dalton JT; Sweatman TW
    Cancer Chemother Pharmacol; 1996; 37(5):472-8. PubMed ID: 8599871
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Doxorubicin pharmacokinetics in the rabbit.
    Maniez-Devos DM; Baurain R; Trouet A; Lesne M
    J Pharmacol; 1985; 16(2):159-69. PubMed ID: 4058012
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The consequences of doxorubicin quinone reduction in vivo in tumour tissue.
    Cummings J; Willmott N; Hoey BM; Marley ES; Smyth JF
    Biochem Pharmacol; 1992 Dec; 44(11):2165-74. PubMed ID: 1472081
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Determination of adriamycin and its fluorescent metabolites in human plasma by HPLC.
    Mahdadi R; Lhermitte M; Lafitte JJ
    Biomed Chromatogr; 1987 Feb; 2(1):38-40. PubMed ID: 3508093
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Metabolism of adriamycin in hepatocytes isolated from the rat and the rabbit.
    Gewirtz DA; Yanovich S
    Biochem Pharmacol; 1987 Jun; 36(11):1793-8. PubMed ID: 3579974
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A method for the simultaneous measurement of the new anthracycline derivative 4'-deoxydoxorubicin and its metabolites by reversed phase liquid chromatography.
    Peng YM; Alberts DS; Salmon SE; Davis TP
    Invest New Drugs; 1984; 2(3):277-80. PubMed ID: 6511234
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics of doxorubicin, (2"R)-4'-O-tetrahydropyranyl-adriamycin and aclarubicin.
    Fujita H; Ogawa K; Tone H; Iguchi H; Shomura T; Murata S
    Jpn J Antibiot; 1986 May; 39(5):1321-36. PubMed ID: 3463778
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative pharmacokinetics of escalating doses of doxorubicin in patients with metastatic breast cancer.
    Bronchud MH; Margison JM; Howell A; Lind M; Lucas SB; Wilkinson PM
    Cancer Chemother Pharmacol; 1990; 25(6):435-9. PubMed ID: 2311172
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New data on the pharmacokinetics of adriamycin and its major metabolite, adriamycinol.
    Leca F; Marchiset-Leca D; Noble A; Antonetti M
    Eur J Drug Metab Pharmacokinet; 1991; 16(2):107-11. PubMed ID: 1936069
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interactions between cyclophosphamide and doxorubicin metabolism in rats. II. Effect of cyclophosphamide on the aldoketoreductase system.
    Dodion P; Akman SR; Tamburini JM; Riggs CE; Colvin OM; Bachur NR
    J Pharmacol Exp Ther; 1986 Apr; 237(1):271-4. PubMed ID: 3514847
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.